Read or download the full Economic Impact Assessment report Read more

The SBC Catalyser Programme

Do you have a winning commercialisation strategy?

The 8-week Catalyser programme helps therapeutics/techbio companies refine their commercialization strategy through a journey involving 12 meso-economic vectors as described by the Triple Chasm model. At the end of the 14 sessions (3 in-person and 11 videocalls) each company gains:

a refined commercialization strategy
a clear execution plan
access to experts, potential partners and investors

Each session is focused on one of the 12 Triple Chasm vectors and includes:

review of each startup strategy on previous vector
presentation of Triple Chasm framework for the current vector
introduction to Triple Chasm tools to help project the theory onto each startup case
panel discussion with 3-4 industry experts to help understand real world scenarios and trend

WHY you should apply

The SBC Catalyser programme provides:

A comprehensive commercial strategy to go from prototype to commercially viable product
A clear execution plan to translate the strategy into action
Support to understand and embed digital and data technologies into your workflow
A strategically aware leadership team, able to evolve their commercialisation strategies in response to changes in markets and technologies
An extended network across the SBC ecosystem; enabling teams to talk to key customers, partners, suppliers and investors
An enhanced company profile
Improved chances of getting the right funding, investment and lab space

HOW to achieve your goals

The programme includes:

Strategy profiling using a range of specialist tools
Commercialisation strategy development workshops focused on the 12 vectors of growth including: positioning, funding, market, IP management, manufacturing, distribution, human capital management
14 sessions over 8 weeks, with panel discussions involving Benevolent AI, Cambridge Innovation Capital, Start Codon, CGT Catapult, Eagle Genomics, o2h, Department of Business and Trade, IQVIA, Redx Pharma, Multiply AI, Virtarka and more.
Being part of the SBC campus and its community including GSK, the Cell and Gene Therapy Catapult (CGTC) and over 40 other growing therapeutics companies
Access to a world class team of mentors and experts, investors and partners
Demo Day and Partnering opportunities

WHO you are

You are developing therapeutic innovations
You have already built a proof of concept and you are planning to create the first commercially viable product
You have integrated digital and data technologies (ie ML/AI) in your R&D workflow, or you are planning to integrate them
You have an existing presence in the UK, or you are planning to establish a presence in the UK
You have an ambitious leadership team of at least 2-3 that can commit to full participation in the programme, including in-person activities at SBC on the first day (23rd May) and the last 2 days (13-14th July).

WHO we are

Campus of 40+ therapeutics companies and largest cluster of CGT companies in Europe
Companies based at SBC have raised more than £2.9bn since SBC's birth in 2012
Our campus also includes GSK, LifeArc, CGTC and Cytiva
We provide lab-space, office-space and business development support to our occupiers
Our Lab Hotel provides free lab-space for 6 months to 4 selected early-stage companies

Read our Economic Impact Assessment report for more information.

Delivered in Collaboration with:

Click here for information on the 2021 "DATA Programme"

2023 Cohort

Be part of SBC Catalyser Programme!

Spaces are limited to 10 companies per cohort. Contact Marco to get more information on our next programme in spring 2024.

Contact Marco

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.